Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16919022 | 0.84 | L3MBTL1 (0.49) | GAAL3MBTL1CYP2C19CYP2C9APOBEC3A | |
| SCHEMBL13456455 | 0.78 | CYP2C9 (0.47) | GAAL3MBTL1CYP2C19CYP2C9MMP2 | |
| SCHEMBL13456452 | 0.78 | CA2 (0.49) | GAAL3MBTL1CYP2C19CYP2C9APOBEC3A | |
| SCHEMBL1576884 | 0.75 | CA12 (0.50) | CA2ALDH1A1KMT2AMEN1 | |
| SCHEMBL16919021 | 0.74 | TLR2 (0.39) | — | |
| SCHEMBL8469243 | 0.72 | MMP2 (0.56) | MMP2KMT2AMEN1 | |
| SCHEMBL8135728 | 0.72 | MMP2 (0.56) | MMP2KMT2AMEN1 | |
| SCHEMBL11235864 | 0.72 | L3MBTL1 (0.64) | GAAL3MBTL1APOBEC3AAPOBEC3GCA2 | |
| SCHEMBL22651724 | 0.71 | MAPK1 (0.33) | KMT2AMEN1 | |
| SCHEMBL372131 | 0.71 | PPARG (0.51) | GAAL3MBTL1CYP2C19CYP2C9APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068272-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068272-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | PLAU, PLAUR, HPN | GAA 111/4885L3MBTL1 3291/4885CYP2C19 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.